Clinical Trial: A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549750) titled 'A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants' on April 07.

Brief Summary: The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are:

1. Does a single dose of HXN5003 in healthy participants impact the safety, tolerability and pharmacokinetic profiles?

2. Will immunogenicity of HXN5003 in healthy participants be altered? This study will be compared against a Placebo which contains the same inactive ingredients as those of HXN5003, but without the active ingredient.

Study Start Da...